Biography
Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.
Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.
Education
| Institution | Degree | Dept or School | End Date |
|---|---|---|---|
| University of California, San Francisco | Post-Doc Fellow/Scholar | Medicine | 1995 |
| University of Alberta | M.D. | School of Medicine | 1987 |
| University of California, San Francisco | Residency | ||
| University of California, San Francisco | Clinical Fellowship | Gastroenterology |
Board Certifications
American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Gastroenterology
Clinical Expertise
Alcoholic Liver Disease
Autoimmune Hepatitis
Benign Liver Tumors
Cirrhosis
Fulminant Hepatic Failure
Hepatitis B
Hepatitis C
Hepatocellular Carcinoma (Liver Cancer)
Live Donor Liver Transplantation
Liver Transplantation
Nonalcoholic Fatty Liver Disease
Pancreas Transplantation
Primary Biliary Cirrhosis
Primary Sclerosing Cholangitis
Clinical Trials
- Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. (NCT01804829)Related Conditions: Hepatitis C, Viruses, Hepatocellular Cancer, Liver Cancer, Hepatitis, Cirrhosis, Liver Transplant| Start Date: | End Date:
- Related Conditions: Hepatitis B, Liver Disease, Liver Transplant| Start Date: | End Date:
Program Affiliations
UCSF Liver Center
In the News
Grants and Funding
- 1/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | NIH | 2023-08-01 - 2030-07-31 | Role: Principal Investigator
- Translational Research Training in Hepatology | NIH | 2022-07-01 - 2027-06-30 | Role: Principal Investigator
- Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | 2002-06-15 - 2027-06-30 | Role: Principal Investigator
- Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis | NIH | 2021-01-01 - 2026-11-30 | Role: Co-Principal Investigator
- USC Cirrhosis Clinical Center | NIH | 2021-09-22 - 2026-08-31 | Role: Principal Investigator
- Hepatitis B Research Network (HBRN): Natural History and Treatment Studies | NIH | 2008-09-30 - 2021-05-31 | Role: Principal Investigator
- Bay Area Hepatitis C Cooperative Research Center | NIH | 2010-06-15 - 2016-05-31 | Role: Co-Investigator
- General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
- Resistance to Antiviral Therapy in Chronic Hepatitis C | NIH | 2001-08-01 - 2007-04-30 | Role: Principal Investigator
Research Narrative
My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.
Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation.
Research Interests
Liver Injury and Repair
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Publications
- Steatotic Liver Disease, Clinical Subtypes, and Adverse Perinatal Outcomes: The Prospective Fatty Liver in Pregnancy Study.| |
PubMed
- Metabolic Dysfunction and Alcohol-Associated Steatotic Liver Disease in Women: Epidemiology, Natural History, and Clinical Outcomes.| |PubMed
- Shared principles within HBV guidelines: aligning clinical approach with differentiated care for global elimination.| |PubMed
- Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.| |PubMed
- Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities.| |PubMed
- Sex-Specific Cardiometabolic Profiles and Severity of Liver Fibrosis.| |PubMed
- Progress Towards Elimination: Hepatitis B and C Among Children and Young Adults in Rural Mongolia.| |PubMed
- A pilot randomized controlled trial of a transportation assistance program in liver transplant (TAP-LT) candidates.| |PubMed
- Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD.| |PubMed
- Reply.| |PubMed